Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects

Schizophrenia Bulletin

Volumn 40, Issue 2, 2014, Pages 287-299

  Smith, Matthew J ^a   Cobia, Derin J ^a   Wang, Lei ^a   Alpert, Kathryn I ^a   Cronenwett, Will J ^a   Goldman, Morris B ^a   Mamah, Daniel ^b   Barch, Deanna M ^b   Breiter, Hans C ^a   Csernansky, John G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

cannabis; marijuana; schizophrenia; structural neuroimaging; working memory

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; CANNABIS; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; COCAINE; NEUROLEPTIC AGENT; NICOTINE; OPIATE; PSYCHEDELIC AGENT; SEDATIVE AGENT;

ADULT; ALCOHOLISM; ARTICLE; BRAIN; BRAIN MAPPING; CANNABIS ADDICTION; CANNABIS USE; CANNABIS USE DISORDER; COCAINE DEPENDENCE; CONTROLLED STUDY; CORPUS STRIATUM; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; GLOBUS PALLIDUS; HISTOPATHOLOGY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEMORY DISORDER; MENTAL PATIENT; MORPHOLOGY; NEUROANATOMY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OPIATE ADDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBCORTEX; SUBSTANCE ABUSE; THALAMUS; WORKING MEMORY; YOUNG ADULT; AGE; COMPARATIVE STUDY; DRUG EFFECTS; MARIJUANA ABUSE; PATHOLOGY; PATHOPHYSIOLOGY; SHORT TERM MEMORY;

ADULT; AGE FACTORS; BRAIN MAPPING; CORPUS STRIATUM; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MARIJUANA ABUSE; MEMORY, SHORT-TERM; SCHIZOPHRENIA; THALAMUS; YOUNG ADULT;

EID: 84903362688     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt176     Document Type: Article

References (70)

1. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. DHHS Publication No. SMA 11-4658. Rockville, MD: Office of Applied Studies; 2011. http://www.oas.samhsa.gov/ NSDUH/2k5nsduh/tabs/2k5Tabs. pdf. March 12, 2013.
2. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2011. Ann Arbor: Institute for Social Research, The University of Michigan; 2012.
3. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109:E2657-E2664.
4. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5:1-8.
5. Bossong MG, Jansma JM, van Hell HH, et al. Effects of δ9- tetrahydrocannabinol on human working memory function. Biol Psychiatry. 2012;71:693-699.
6. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev. 2008;1:81-98.
7. Baddeley A. Working memory. Science. 1992;255:556-559.
8. Sales-Carbonell C, Rueda-Orozco PE, Soria-Gomez E, Buzsaki G, Marsicano G, Robbe D. Striatal GABAergic and cortical glutamatergic neurons mediate contrasting effects of cannabinoids on cortical network synchrony. Proc Natl Acad Sci U S A. 2013;110:719-724.
9. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89:309-380.
10. Tebano MT, Martire A, Popoli P. Adenosine A(2A)- cannabinoid CB(1) receptor interaction: an integrative mechanism in striatal glutamatergic neurotransmission. Brain Res. 2012;1476:108-118.
11. Schroll H, Vitay J, Hamker FH. Working memory and response selection: a computational account of interactions among cortico-basalganglio-thalamic loops. Neural Netw. 2012;26:59-74.
12. Bonelli RM, Cummings JL. Frontal-subcortical circuitry and behavior. Dialogues Clin Neurosci. 2007;9:141-151.
13. Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - a short review. Pharmacol Biochem Behav. 2008;90:501-511.
14. Batalla A, Bhattacharyya S, Yucel M, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One. 2013;8:e55821.
15. Lorenzetti V, Solowij N, Fornito A, Lubman D, Yucel M. The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature. Curr Pharm Des. In press.
16. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6:348-357.
17. Forbes NF, Carrick LA, McIntosh AM, Lawrie SM. Working memory in schizophrenia: a meta-Analysis. Psychol Med. 2009;39:889-905.
18. Byne W, Hazlett EA, Buchsbaum MS, Kemether E. The thalamus and schizophrenia: current status of research. Acta Neuropathol. 2009;117:347-368.
19. Ballmaier M, Schlagenhauf F, Toga AW, et al. Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia. Schizophr Res. 2008;106:140-147.
20. Csernansky JG, Schindler MK, Splinter NR, et al. Abnormalities of thalamic volume and shape in schizophrenia. Am J Psychiatry. 2004;161:896-902.
21. Mamah D, Wang L, Barch D, de Erausquin GA, Gado M, Csernansky JG. Structural analysis of the basal ganglia in schizophrenia. Schizophr Res. 2007;89:59-71.
22. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/ schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009;259:413-431.
23. Yucel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-Analysis of existing findings and new data in a firstepisode sample. Schizophr Bull. 2012;38:316-330.
24. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature. 2010;468:203-212.
25. Thoma P, Daum I. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin Neurosci. 2013;67:367-383.
26. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50:71-83.
27. Green AI, Salomon MS, Brenner MJ, Rawlins K. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets CNS Neurol Disord. 2002;1:129-139.
28. Wobrock T, Hasan A, Malchow B, et al. Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. Psychopharmacology (Berl). 2010;208:353-363.
29. Walter M, Denier N, Vogel M, Lang UE. Effects of psychoactive substances in schizophrenia - findings of structural and functional neuroimaging. Curr Top Med Chem. 2012;12:2426-2433.
30. Malchow B, Hasan A, Fusar-Poli P, Schmitt A, Falkai P, Wobrock T. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur Arch Psychiatry Clin Neurosci. 2013;263:3-13.
31. Solowij N, Walterfang M, Lubman DI, et al. Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr Res. 2013;143:179-184.
32. Csernansky JG, Wang L, Joshi SC, Ratnanather JT, Miller MI. Computational anatomy and neuropsychiatric disease: probabilistic assessment of variation and statistical inference of group difference, hemispheric asymmetry, and time-dependent change. Neuroimage. 2004;23(suppl 1):S56-S68.
33. Makris N, Gasic GP, Seidman LJ, et al. Decreased absolute amygdala volume in cocaine addicts. Neuron. 2004;44:729-740.
34. Makris N, Gasic GP, Kennedy DN, et al. Cortical thickness abnormalities in cocaine addiction - a reflection of both drug use and a pre-existing disposition to drug abuse? Neuron. 2008;60:174-188.
35. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9:97-113.
36. Hollingshead AB. Four Factor Index of Social Status. New Haven, CT: Department of Sociology, Yale University; 1975.
37. First MB, Spitzer RL, Miriam G, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
38. Mennes CE, Ben Abdallah A, Cottler LB. The reliability of self-reported cannabis abuse, dependence and withdrawal symptoms: multisite study of differences between general population and treatment groups. Addict Behav. 2009;34:223-226.
39. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67:255-262.
40. Smith MJ, Barch DM, Wolf TJ, Mamah D, Csernansky JG. Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophrenia. Schizophr Res. 2008;106:294-299.
41. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29-39.
42. Wechsler D. Wechsler Memory Scale - Third Edition. San Antonio, TX: The Psychological Corporation; 1997.
43. Barch DM, Mitropoulou V, Harvey PD, New AS, Silverman JM, Siever LJ. Context-processing deficits in schizotypal personality disorder. J Abnorm Psychol. 2004;113:556-568.
44. Enders CK. Applied Missing Data Analysis. New York, NY: Guildford Press; 2010.
45. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch Gen Psychiatry. 1995;52:341-351.
46. Venkatesan R, Haacke EM. Role of high resolution in magnetic resonance (MR) imaging: applications for MR angiography, intracranial T1-weighted imaging, and image interpolation. Int J Imag Syst Tech. 1997;8:529-543.
47. Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23:724-738.
48. Mai J, Assheuer J, Paxinos G. Atlas of the Human Brain. San Diego, CA: Academic Press; 1997.
49. Wang L, Mamah D, Harms MP, et al. Progressive deformation of deep brain nuclei and hippocampal-Amygdala formation in schizophrenia. Biol Psychiatry. 2008;64:1060-1068.
50. Park S, Knopick C, McGurk S, Meltzer HY. Nicotine impairs spatial working memory while leaving spatial attention intact. Neuropsychopharmacology. 2000;22:200-209.
51. Reilly JL, Harris MS, Khine TT, Keshavan MS, Sweeney JA. Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biol Psychiatry. 2007;62:818-821.
52. Brody AL, Mandelkern MA, Jarvik ME, et al. Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biol Psychiatry. 2004;55:77-84.
53. Goldman-Rakic PS. Cellular basis of working memory. Neuron. 1995;14:477-485.
54. Lewis DA, Cho RY, Carter CS, et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry. 2008;165:1585-1593.
55. Toga AW, Thompson PM. Mapping brain asymmetry. Nat Rev Neurosci. 2003;4:37-48.
56. Eidelberg D, Galaburda AM. Symmetry and asymmetry in the human posterior thalamus. I. Cytoarchitectonic analysis in normal persons. Arch Neurol. 1982;39:325-332.
57. Watkins KE, Paus T, Lerch JP, et al. Structural asymmetries in the human brain: a voxel-based statistical analysis of 142 MRI scans. Cereb Cortex. 2001;11:868-877.
58. Petty RG. Structural asymmetries of the human brain and their disturbance in schizophrenia. Schizophr Bull. 1999;25:121-139.
59. Medina KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry. Neurotoxicol Teratol. 2007;29:141-152.
60. Harms MP, Wang L, Mamah D, Barch DM, Thompson PA, Csernansky JG. Thalamic shape abnormalities in individuals with schizophrenia and their nonpsychotic siblings. J Neurosci. 2007;27:13835-13842.
61. Mamah D, Harms MP, Wang L, et al. Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patients. Biol Psychiatry. 2008;64:111-120.
62. Qiu A, Zhong J, Graham S, Chia MY, Sim K. Combined analyses of thalamic volume, shape and white matter integrity in first-episode schizophrenia. Neuroimage. 2009;47:1163-1171.
63. Coscia DM, Narr KL, Robinson DG, et al. Volumetric and shape analysis of the thalamus in first-episode schizophrenia. Hum Brain Mapp. 2009;30:1236-1245.
64. Welch KA, Stanfield AC, McIntosh AM, et al. Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia. Br J Psychiatry. 2011;199:386-390.
65. Ferraro L, Russo M, O'Connor J, et al. Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res. 2013;150:129-135.
66. Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol. 2010;92:370-385.
67. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558-1572.
68. Kolb B, Gorny G, Limebeer CL, Parker LA. Chronic treatment with delta-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats. Synapse. 2006;60:429-436.
69. James A, Hough M, James S, et al. Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). Schizophr Res. 2011;128:91-97.
70. Fernandez-Ruiz J, Hernandez M, Ramos JA. Cannabinoiddopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther. 2010;16:e72-e91.